1、WelcomeContentClick below to navigate through the documentReflections on 2025Top 10 questions from shareholdersSelect topics at forthcoming AGM Edition no.24 Q4 2025 Impact and Sustainability Update to Investors For any questions and comments,please reach out to:Sloan SimpsonGlobal Head of Investor

2、R+1 862 345 4440Maria Victoria CuevasInvestor Relations Executive Director&ESG H+41 79 586 52 85Dear investors and analysts,Our Q4 update summarizes our 2025 progress and reflections on impact and sustainability,including our breakthrough innovation in malaria and industry-leading recognition from t

3、hird-party ratings.We also cover select topics from our upcoming AGM.As always,we also include top questions from shareholders during Q4 and our responses.We thank you for your continued engagement.Q4 impact and sustainability update|2WelcomeContentClick below to navigate through the documentReflect

4、ions on 2025Top 10 questions from shareholdersSelect topics at forthcoming AGM Reflections on 20252025 was another strong year for Novartis.During the year,we advanced our strategy while delivering meaningful impact for patients around the world.In an environment shaped by rapid scientific progress

5、and evolving policy including our recent pricing agreement with the US government we continued to lead in our core therapeutic areas and technology platforms,advance our pipeline,and execute with discipline to deliver long-term value for patients and shareholders.In total,we reached more than 300 mi

6、llion patients across 118 countries,including 30 million through our dedicated access approaches1.We further evolved our social impact&sustainability strategy to strengthen alignment with the business and bring increased focus to our impact.We delivered strong performance against our 2025 targets,in